Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Breast Cancer (Tokyo, Japan)|August 14, 2024
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabineRui Kitadai, Tatsunori Shimoi, Shu Yazaki, et al.
BMC Cancer|November 26, 2022
High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: a retrospective studyShigemasa Takamizawa, Shu Yazaki, Yuki Kojima, et al.
British Journal of Cancer|December 15, 2022
Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancerShu Yazaki, Roberto Salgado, Tatsunori Shimoi, et al.
Diagnostics (Basel, Switzerland)|June 28, 2023
Development of a Detection System for <i>ESR1</i> Mutations in Circulating Tumour DNA Using PNA-LNA-Mediated PCR ClampingYuki Kojima, Emi Noguchi, Tomomi Yoshino, et al.
Gynecologic Oncology|May 9, 2024
Trop-2 expression and the tumor immune microenvironment in cervical cancerYohei Chiba, Yuki Kojima, Shu Yazaki, et al.
Journal of Gynecologic Oncology|October 17, 2022
High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancerShu Yazaki, Yuki Kojima, Hiroshi Yoshida, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|June 24, 2024
Folate Receptor Alpha Expression and the Tumor Immune Microenvironment in Patients with Cervical CancerShu Yazaki, Yohei Chiba, Yuki Kojima, et al.
Oncology|April 11, 2022
Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial SarcomaYuki Kojima, Tatsunori Shimoi, Takuji Seo, et al.
Virchows Archiv : an International Journal of Pathology|September 5, 2023
Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancerJun Miyakoshi, Shu Yazaki, Tatsunori Shimoi, et al.
Scientific Reports|July 3, 2023
Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapySho Watanabe, Tatsunori Shimoi, Tadaaki Nishikawa, et al.
Pageof 4